Q-1802

N/A

Report date: 2023/05/18 20:00:22

Base Information

Drug NameQ-1802

Drug Alias NameQ-1802

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionProgrammed death-ligand 1 blockersAnti-CLDN18

TargetsClaudin-18 splice variant 2Programmed death-ligand 1

Therapy Area/IndicationsSolid tumoursEsophageal NeoplasmsGastrointestinal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesQure Biotechnology (Shanghai) Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesQure Biotechnology (Shanghai) Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursEsophageal NeoplasmsGastrointestinal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A